4/A: Inscobee Amends SEC Filing on Apimeds US Share Ownership
Amendment to Statement of Changes in Beneficial Ownership
Inscobee Inc. filed an amended Form 4 to clarify its direct and indirect beneficial ownership of Apimeds Pharmaceuticals US, Inc. common stock.
Summary
- Inscobee Inc. filed an amendment (Form 4/A) to a previous Form 4 filing for Apimeds Pharmaceuticals US, Inc. (APUS).
- The amendment's sole purpose is to correct previously misreported beneficial ownership details related to Apimeds Inc. (Apimeds Korea).
- As of May 12, 2025, Inscobee Inc. directly held 2,099,747 shares of Apimeds Pharmaceuticals US, Inc. common stock.
- Inscobee Inc. also indirectly held 4,316,618 shares of common stock through its wholly-owned subsidiary, Apimeds Inc. (Apimeds Korea).
- The reporting person disclaims beneficial ownership of the 4,316,618 shares held by Apimeds Korea for purposes of Section 16 or any other purpose.
Sentiment
Score: 6
Explanation: The filing corrects previous errors, which is a positive for transparency, but the need for multiple amendments indicates initial reporting issues. The disclaimer of beneficial ownership for a subsidiary's holdings is a standard practice for Section 16 purposes.
Positives
- The filing increases transparency and accuracy in reporting beneficial ownership.
- Correction of previous errors ensures compliance with SEC regulations.
Negatives
- The need for multiple amendments (original Form 4, first amendment, and this amendment) indicates initial reporting inaccuracies.
Risks
- Potential for investor confusion due to multiple amendments and initial reporting errors.
- Risk of non-compliance if reporting errors are not promptly identified and corrected.
Future Outlook
NA
Management Comments
- The reporting person disclaims beneficial ownership of these securities (4,316,618 shares held by Apimeds Korea), and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- This amendment is being filed solely to correct Apimeds Korea's reported holdings.
Industry Context
This filing is a routine regulatory disclosure required for insiders and significant shareholders, providing transparency on ownership changes. It does not directly relate to broader industry trends but ensures compliance within the pharmaceutical sector's regulatory framework.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reporting Clarification | Correction of beneficial ownership reporting for a 10% owner and director, ensuring accurate disclosure of direct and indirect holdings. | 11/21/2025 | Enhances transparency and regulatory compliance regarding insider ownership, which is a core aspect of corporate governance. |
Related Party Transactions
- The filing clarifies the indirect beneficial ownership of Inscobee Inc. through its wholly-owned subsidiary, Apimeds Inc. (Apimeds Korea), which represents a related party relationship in terms of ownership structure.
Stakeholder Impact
- Shareholders: Provides clearer information on the beneficial ownership structure of a significant shareholder (Inscobee Inc.), aiding in investment decisions and understanding control.
- Regulatory Authorities: Ensures compliance with SEC reporting requirements, maintaining market integrity.
Next Steps
- Continued compliance with Section 16 reporting requirements for future transactions involving Apimeds Pharmaceuticals US, Inc. securities.
Key Dates
| Date | Description |
|---|---|
| 05/12/2024 | Date of earliest transaction related to the reported beneficial ownership. |
| 05/14/2025 | Date the original Form 4 was filed, which incorrectly reported indirect beneficial ownership of a Convertible Promissory Note and underlying shares. |
| 06/11/2025 | Date of the first amendment to the Form 4, which reported direct ownership of the Note and Shares by Inscobee Inc. but did not update Apimeds Korea's holdings. |
| 11/21/2025 | Date this current amendment (Form 4/A) was filed, solely to correct Apimeds Korea's reported holdings. |
Keywords
Inscobee Inc., Apimeds Pharmaceuticals US Inc., APUS, Form 4/A, beneficial ownership, common stock, SEC filing, insider trading, corporate governance, amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.